Cancer Therapy News and Research

RSS

NSHOA and Caris Life Sciences collaborate to establish personalized cancer care program

North Shore Hematology Oncology Associates and Caris Life Sciences today announced a collaboration to establish a personalized cancer care program for patients in the greater Long Island area.

12 May 2014

Researchers reveal how protein acts as brake against pathological growth of heart muscle

Cardiovascular disease remains the number one cause of death in the Western world, with heart failure representing the fastest-growing subclass over the past decade.

12 May 2014

Three NSU professors secure patents for their innovations

Three Nova Southeastern University's (NSU) professors from three different colleges recently secured patents for their innovations.

9 May 2014

Johns Hopkins cancer center gets $10M gift for breast cancer-related programs

Officials at the Johns Hopkins Kimmel Cancer Center today announced receipt of a $10 million gift from Under Armour Inc. to fund breast cancer and breast health support programs and a women’s wellness center.

9 May 2014

Wake Forest Baptist Medical Center finds novel treatment to keep lung cancer at bay

An old idea of retreating lung tumors with radiation is new again, especially with the technological advances seen in radiation oncology over the last decade.

9 May 2014

Johns Hopkins to use $65 million gift to expand Sidney Kimmel Comprehensive Cancer Center

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins will use a $65 million gift toward the construction of a new patient care building that will be named for the late Albert P. “Skip” Viragh, Jr., a Maryland mutual fund investment leader and philanthropist.

7 May 2014

NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna Breast Cancer Prognostic Gene Signature Assay for assessing a woman's 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.

From NanoString Technologies 7 May 2014

Rice University researchers find new possibilities for benign, 'tunable' virus

Rice University scientists have designed a tunable virus that works like a safe deposit box. It takes two keys to open it and release its therapeutic cargo.

7 May 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

NCCN publishes new patient resource for stage 0 breast cancer

The National Comprehensive Cancer Network (NCCN), with the support of the NCCN Foundation®, announces the availability of the NCCN Guidelines for Patients: Breast Cancer Stages 0 - IV—the latest addition to the library of NCCN Guidelines for Patients available online free-of-charge at NCCN.org/patients.

6 May 2014

Novogen partners with Genea Biocells to accelerate testing for neurodegenerative diseases

Novogen Limited, an oncology drug development company, today announced a collaboration with Australian company, Genea Biocells, to accelerate testing of their super-benzopyran (SBP) drugs for degenerative diseases of the nervous system and muscles.

5 May 2014

Research: Novel therapeutic approach to overcome chemoresistance in ovarian cancer

Inhibiting enzymes that cause changes in gene expression could decrease chemotherapy resistance in ovarian cancer patients, researchers at Georgia State University and the University of Georgia say.

5 May 2014

Newly discovered molecule provides drug target for controlling both asthma and cancerous tumor growth

A newly discovered molecule provides a new drug target for controlling both asthma-induced muscle thickening and cancerous tumor growth. This molecule, called "microRNA-10a," normally helps genes produce proteins or make copies of themselves, also play an important role in the growth or overgrowth of human airway smooth muscle cells and some forms of cancer.

2 May 2014

Findings suggest usage of statins after surgery may reduce risk of prostate cancer recurrence

Men who begin taking statins after prostate cancer surgery are less likely to have a recurrence of their cancer, according to a retrospective analysis led by researchers at Duke Medicine.

2 May 2014

Biotech to the rescue

MIT professor Ram Sasisekharan's three biotech companies — Momenta Pharmaceuticals, Cerulean Pharma, and Visterra — share a similar goal.

1 May 2014

Sun tanning equals skin damage: New awareness campaign

It only takes a few bad sunburns or trips to the tanning bed to put someone at risk for melanoma. Skin cancer is the most common type of cancer in the United States and when left untreated, melanoma is the most dangerous and aggressive form. It accounts for more than 9,000 of the 12,000-plus skin cancer deaths each year. In observance of May's Melanoma and Skin Cancer Awareness Month Seattle Cancer Care Alliance (SCCA) is focusing on helping teens keep their skin safe this spring with a new infographic.

1 May 2014

Investigators find that major lung surgery has become safer over last few decades

A major new study using data from the National Cancer Data Base details the impact of annual hospital volume on 30- and 90-day mortality rates.

30 Apr 2014

Researchers develop new strategy to personalised medicine in advanced cancer patients

Tumour cells can accumulate hundreds or even thousands of DNA mutations which induce the growth and spread of cancer. The number and pattern of mutations differs according to the type of tumour, even among those that are classified as part of the same type of tumours.

30 Apr 2014

First Edition: April 28, 2014

Today's headlines include a number of stories examining the impact of the health law in various states.

28 Apr 2014

Women who had chemotherapy less likely to be employed 4 years later

Nearly one-third of breast cancer survivors who were working when they began treatment were unemployed four years later. Women who received chemotherapy were most affected, according to a new study from the University of Michigan Comprehensive Cancer Center.

28 Apr 2014

Cancer Therapy News and Research

NSHOA and Caris Life Sciences collaborate to establish personalized cancer care program

Researchers reveal how protein acts as brake against pathological growth of heart muscle

Three NSU professors secure patents for their innovations

Johns Hopkins cancer center gets $10M gift for breast cancer-related programs

Wake Forest Baptist Medical Center finds novel treatment to keep lung cancer at bay

Johns Hopkins to use $65 million gift to expand Sidney Kimmel Comprehensive Cancer Center

NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay

Rice University researchers find new possibilities for benign, 'tunable' virus

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

NCCN publishes new patient resource for stage 0 breast cancer

Novogen partners with Genea Biocells to accelerate testing for neurodegenerative diseases

Research: Novel therapeutic approach to overcome chemoresistance in ovarian cancer

Newly discovered molecule provides drug target for controlling both asthma and cancerous tumor growth

Findings suggest usage of statins after surgery may reduce risk of prostate cancer recurrence

Biotech to the rescue

Sun tanning equals skin damage: New awareness campaign

Investigators find that major lung surgery has become safer over last few decades

Researchers develop new strategy to personalised medicine in advanced cancer patients

First Edition: April 28, 2014

Women who had chemotherapy less likely to be employed 4 years later

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News